Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
CLVS
Top 10 Correlated ETFs
CLVS
Top 10 Correlated Stocks
CLVS
In the News
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Why Clovis Oncology Stock Is Sinking Today
The biotech's Q2 financial results are concerning investors today.
Why Is Clovis Oncology (CLVS) Stock Down 10% Today?
Clovis Oncology (NASDAQ: CLVS ) stock is down more than 10% today after posting its second-quarter financial results. The biopharmaceutical company missed on revenue and profits, leading the way for today's selloff.
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2022 Results - Earnings Call Transcript
Clovis Oncology, Inc. (NASDAQ:CLVS ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Anna Sussman - VP, IR Patrick Mahaffy - Co-Founder, CEO, President & Executive Director Lindsey Rolfe - EVP, Clinical Development & Pharmacovigilance and Chief Medical Officer Daniel Muehl - EVP & CFO Conference Call Participants Operator Good morning. My name is Samantha, and I will be your conference operator today.
7 Penny Stocks to Buy Before the Bull Market Returns
In recent weeks, the stock market has stabilized after June's sell-off, but it may take time before bullishness makes a comeback. Plenty of uncertainty remains, including further interest rate hikes, continued high inflation, and the growing chance of a recession.
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--First paragraph, second sentence of release should read: Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis' results and business outlook in greater detail. (instead of Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail.). The updated release reads: CLOVIS ONCOLOGY TO ANNOUNCE SECOND QUARTER 2022 FINANC
Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail. The conference call will be simultaneously webcas
Why Clovis Oncology Stock Trounced the Market Today
Investors were cheered by news of a freshly signed supply deal.
Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement
CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.
Why Clovis Oncology Stock Went Into Retreat Mode This Week
After a massive surge in its share price recently, Clovis Oncology has started to reverse course.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.18 | 1.83 | 2.65 | 1.95 | 1.23 | |
| Net income per share | -7.36 | -7.07 | -7.43 | -4.38 | -2.18 | |
| Operating cash flow per share | -5.55 | -7.03 | -6.01 | -3 | -1.62 | |
| Free cash flow per share | -5.63 | -8.26 | -6.36 | -3.1 | -1.62 | |
| Cash per share | 11.98 | 9.99 | 5.51 | 2.85 | 1.18 | |
| Book value per share | 7.81 | 2.81 | -3.23 | -1.88 | -2.3 | |
| Tangible book value per share | 6.01 | 0.6 | -5.57 | -3.41 | -3.32 | |
| Share holders equity per share | 7.81 | 2.81 | -3.23 | -1.88 | -2.3 | |
| Interest debt per share | 6.22 | 11.33 | 13.02 | 7.95 | 5.53 | |
| Market cap | 2.87B | 1.28B | 464.39M | 666.03M | 233.95M | |
| Enterprise value | 2.69B | 1.64B | 987.7M | 1.07B | 728.89M | |
| P/E ratio | -8.28 | -3.48 | -1.16 | -1.8 | -0.88 | |
| Price to sales ratio | 51.67 | 13.43 | 3.25 | 4.05 | 1.57 | |
| POCF ratio | -10.99 | -3.5 | -1.43 | -2.64 | -1.19 | |
| PFCF ratio | -10.82 | -2.98 | -1.36 | -2.55 | -1.19 | |
| P/B Ratio | 7.8 | 8.74 | -2.66 | -4.2 | -0.84 | |
| PTB ratio | 7.8 | 8.74 | -2.66 | -4.2 | -0.84 | |
| EV to sales | 48.4 | 17.15 | 6.91 | 6.52 | 4.9 | |
| Enterprise value over EBITDA | -7.97 | -4.68 | -2.64 | -3.17 | -3.24 | |
| EV to operating cash flow | -10.3 | -4.47 | -3.05 | -4.24 | -3.72 | |
| EV to free cash flow | -10.14 | -3.8 | -2.88 | -4.11 | -3.71 | |
| Earnings yield | -0.12 | -0.29 | -0.86 | -0.55 | -1.13 | |
| Free cash flow yield | -0.09 | -0.34 | -0.74 | -0.39 | -0.84 | |
| Debt to equity | 0.77 | 3.93 | -3.9 | -3.64 | -2.25 | |
| Debt to assets | 0.5 | 0.83 | 1.26 | 1.26 | 1.59 | |
| Net debt to EBITDA | 0.54 | -1.01 | -1.4 | -1.2 | -2.2 | |
| Current ratio | 7.69 | 4.55 | 2.75 | 1.68 | 1.58 | |
| Interest coverage | -22.79 | -25.32 | -22.77 | -12.86 | -7.13 | |
| Income quality | 0.75 | 0.99 | 0.81 | 0.68 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.5 | 1.84 | 1.28 | 0 | 0 | |
| Research and developement to revenue | 2.57 | 2.43 | 1.98 | 1.57 | 1.29 | |
| Intangibles to total assets | 0.12 | 0.13 | 0.19 | 0.21 | 0.26 | |
| Capex to operating cash flow | 0.02 | 0.18 | 0.06 | 0.03 | 0 | |
| Capex to revenue | -0.07 | -0.67 | -0.13 | -0.05 | 0 | |
| Capex to depreciation | -1.64 | -13.96 | -2.45 | -1.02 | -0.04 | |
| Stock based compensation to revenue | 0.81 | 0.51 | 0.38 | 0.31 | 0.17 | |
| Graham number | 35.98 | 21.15 | 23.26 | 13.62 | 10.63 | |
| ROIC | -0.36 | -0.45 | -0.7 | -0.72 | -0.65 | |
| Return on tangible assets | -0.53 | -0.49 | -0.74 | -0.77 | -0.76 | |
| Graham Net | 4.59 | -3.3 | -9.43 | -5.76 | -4.75 | |
| Working capital | 545.42M | 446.55M | 233.38M | 125.9M | 72.87M | |
| Tangible asset value | 282.86M | 31.47M | -300.25M | -287.57M | -402.29M | |
| Net current asset value | 259.35M | -144.79M | -477.39M | -453.47M | -553.59M | |
| Invested capital | 0.77 | 3.94 | -3.93 | -4.08 | -2.29 | |
| Average receivables | 19.41M | 22.88M | 32.63M | 30.6M | 32.14M | |
| Average payables | 20.92M | 27.6M | 29.46M | 26.69M | 27M | |
| Average inventory | 29.11M | 28.89M | 28.62M | 30.71M | 22.2M | |
| Days sales outstanding | 54 | 58.02 | 88.46 | 67.88 | 82.62 | |
| Days payables outstanding | 471.04 | 471.54 | 339.23 | 235.87 | 256.72 | |
| Days of inventory on hand | 855.45 | 447.64 | 279.06 | 271.41 | 128.68 | |
| Receivables turnover | 6.76 | 6.29 | 4.13 | 5.38 | 4.42 | |
| Payables turnover | 0.77 | 0.77 | 1.08 | 1.55 | 1.42 | |
| Inventory turnover | 0.43 | 0.82 | 1.31 | 1.34 | 2.84 | |
| ROE | -0.94 | -2.51 | 2.3 | 2.33 | 0.95 | |
| Capex per share | -0.09 | -1.23 | -0.35 | -0.1 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-03-31 for Q1
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.37 | 0.34 | 0.31 | 0.3 | 0 | |
| Net income per share | -0.64 | -0.61 | -0.56 | -0.53 | 0 | |
| Operating cash flow per share | -0.59 | -0.43 | -0.38 | -0.34 | -0.48 | |
| Free cash flow per share | -0.59 | -0.43 | -0.38 | -0.34 | -0.48 | |
| Cash per share | 1.83 | 2.12 | 1.42 | 1.18 | 1.01 | |
| Book value per share | -2.12 | -1.91 | -1.86 | -2.3 | -2.5 | |
| Tangible book value per share | -3.34 | -3.07 | -2.89 | -3.32 | -2.51 | |
| Share holders equity per share | -2.12 | -1.91 | -1.86 | -2.3 | -2.5 | |
| Interest debt per share | 6.44 | 6.28 | 5.21 | 5.33 | 3.61 | |
| Market cap | 731.81M | 629.19M | 540.63M | 328.5M | 244.86M | |
| Enterprise value | 1.21B | 1.07B | 992.3M | 823.44M | 559.9M | |
| P/E ratio | -2.76 | -2.37 | -2 | -1.28 | 0 | |
| Price to sales ratio | 19.23 | 17.09 | 14.26 | 9.13 | 0 | |
| POCF ratio | -11.82 | -13.46 | -11.74 | -7.95 | -4.19 | |
| PFCF ratio | -11.8 | -13.45 | -11.71 | -7.93 | -4.19 | |
| P/B Ratio | -3.31 | -3.04 | -2.4 | -1.18 | -0.81 | |
| PTB ratio | -3.31 | -3.04 | -2.4 | -1.18 | -0.81 | |
| EV to sales | 31.67 | 29.1 | 26.17 | 22.89 | 0 | |
| Enterprise value over EBITDA | -21.23 | -19.11 | -17.35 | -15.05 | 0 | |
| EV to operating cash flow | -19.47 | -22.92 | -21.54 | -19.92 | -9.57 | |
| EV to free cash flow | -19.44 | -22.9 | -21.5 | -19.88 | -9.57 | |
| Earnings yield | -0.09 | -0.11 | -0.12 | -0.2 | 0 | |
| Free cash flow yield | -0.08 | -0.07 | -0.09 | -0.13 | -0.24 | |
| Debt to equity | -2.69 | -2.92 | -2.75 | -2.25 | -1.44 | |
| Debt to assets | 1.4 | 1.36 | 1.44 | 1.59 | 1.67 | |
| Net debt to EBITDA | -8.34 | -7.89 | -7.9 | -9.05 | 0 | |
| Current ratio | 1.46 | 1.7 | 2.05 | 1.58 | 0 | |
| Interest coverage | -7.84 | -7.07 | -7.03 | -6.63 | 0 | |
| Income quality | 0.93 | 0.7 | 0.68 | 0.64 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.39 | 1.3 | 1.31 | 1.16 | 0 | |
| Intangibles to total assets | 0.23 | 0.22 | 0.25 | 0.26 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.05 | -0.02 | -0.04 | -0.03 | 0 | |
| Stock based compensation to revenue | 0.11 | 0.2 | 0.18 | 0.2 | 0 | |
| Graham number | 5.51 | 5.13 | 4.82 | 5.24 | 0 | |
| ROIC | -0.15 | -0.14 | -0.15 | -0.15 | 0 | |
| Return on tangible assets | -0.16 | -0.15 | -0.18 | -0.18 | 0 | |
| Graham Net | -5.26 | -4.74 | -4.37 | -4.75 | -5.22 | |
| Working capital | 79.28M | 122.47M | 117.97M | 72.87M | 0 | |
| Tangible asset value | -348.51M | -333.11M | -350.25M | -402.29M | -304.65M | |
| Net current asset value | -517.36M | -482.86M | -502.79M | -553.59M | -632.59M | |
| Invested capital | -3.01 | -3.25 | -2.77 | -2.29 | -1.44 | |
| Average receivables | 30.06M | 31.75M | 32.47M | 33.67M | 0 | |
| Average payables | 23.91M | 24.89M | 25.57M | 27.31M | 0 | |
| Average inventory | 17.93M | 19.34M | 15.48M | 13.69M | 0 | |
| Days sales outstanding | 62.54 | 72.9 | 74.19 | 84.26 | 0 | |
| Days payables outstanding | 191.99 | 209.93 | 217.71 | 252.59 | 0 | |
| Days of inventory on hand | 207.57 | 233.41 | 157.88 | 126.61 | 0 | |
| Receivables turnover | 1.44 | 1.23 | 1.21 | 1.07 | 0 | |
| Payables turnover | 0.47 | 0.43 | 0.41 | 0.36 | 0 | |
| Inventory turnover | 0.43 | 0.39 | 0.57 | 0.71 | 0 | |
| ROE | 0.3 | 0.32 | 0.3 | 0.23 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Company Profile
- Volume Average 13.06M
- Market Capitalization 238.84M
- Employee 413
- CEO Mr. Patrick Mahaffy
- Headquarters Boulder,COLORADO,US
- IPO Date 2011-11-16
-
Website
https://www.clovisoncology.com 
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
